Replies to post #233 on Atossa Therapeutics Inc (ATOS)

[ncoulb1]

Exactly, Atossa just needs exposure.. and you can bet they will be getting just that during this coming month.

[rwwine]

Thank you in kind for your reply. I do appreciate a spirited exchange. While I agree that retail investors may take an interest in ATOS this October with the focus on "Breast Health", I still feel that the investment community (Wall Street) won't take much of an interest until such time that ATOS shows significant growth and a projected timeline when they break even. When this happens, I too think this company will really take off. If ATOS gets 1% of the 38 Million mammograms to convert to the ForeCYTE Breast Health Test™, that would represent an impressive $220 Million in sales revenue (minus commissions paid to account managers & or distributors....I am estimating 45% in my mathematical models for now). If and when ForeCYTE Breast Health Test™ becomes the standard care for breast health monitoring, the numbers are staggering. Please feel free to question my thought process......TIA